To Fight Drug Shortages FDA Has an Idea: Import More Inspection-Free Drugs
The balance between scarcity and supply favors supply, even if that means importing drugs from labs the FDA has not inspected.
The balance between scarcity and supply favors supply, even if that means importing drugs from labs the FDA has not inspected.
The U.S. is increasingly reliant on imported drugs from uninspected labs. It’s not safe. What can be done about it?
A Senate hearing on pharmaceutical shortages discusses America’s dependence on India and China, and what can be done to reshore.
The Senate Commerce Committee takes the little known, and even less understood, Pharmacy Benefit Manager industry to task for high drug costs.
The U.S. is increasingly dependent on imports for drugs. One reason: a tax avoidance scheme that pits U.S. manufacturing up against Europe. What can be done about this problem?
The Covid-19 pandemic gave big pharma big payday. But it also caused the industry to rethink a globalized supply chain centered on Asia. What will it take to reshore at least some generic drugs to the U.S.
U.S. pharmaceutical imports have skyrocketed in the last ten years, with imports from China, India and Mexico leading the surge.
A Senate Commerce subcommittee hearing heard from witnesses who said worker shortages will ultimately be a drag on U.S. reshoring efforts. Pharmaceutical reps warned of high energy costs, which could add to import dependence.
One of India’s pharmaceutical labs has run afoul of the FDA many times this year. The U.S. is dependent on foreign labs like Aurobindo for its drug supply. Can the government help change that?
A project out of the Department of Health & Human Services promises more domestic supply of locally made vaccines and critical drugs. Will they finally deliver?